Adaptive Biotechnologies (NASDAQ:ADPT) Shares Break Above 50 Day Moving Average Following Insider Selling

Key Points

• Adaptive Biotechnologies beat quarterly expectations: It reported EPS of $0.02 versus analysts’ expected loss of $0.10, while revenue of $83.9 million exceeded estimates. However, revenue fell 10.7% year over year, and the company still posted a negative net margin.
• Shares rose 3.5% and moved above their 50-day moving average of $26.37, trading as high as $26.88.
• Analyst sentiment is generally positive: six analysts rate ADPT a Buy, with a consensus price target of $30.06. COO Julie Rubinstein sold 11,881 shares under a pre-arranged trading plan and retained 377,802 shares.

Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) shares crossed above its 50 day moving average during trading on Wednesday following insider buying activity. The stock has a 50 day moving average of $26.37 and traded as high as $26.88. Adaptive Biotechnologies shares last traded at $26.71, with a volume of 2,326,040 shares changing hands.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ADPT. BTIG Research increased their price objective on shares of Adaptive Biotechnologies from $25.00 to $34.00 and gave the company a "buy" rating in a research report on Tuesday, September 22nd. Guggenheim raised their target price on shares of Adaptive Biotechnologies from $25.00 to $32.00 and gave the stock a "buy" rating in a research note on Thursday, October 1st. Piper Sandler lifted their target price on shares of Adaptive Biotechnologies from $20.00 to $27.50 and gave the stock an "overweight" rating in a report on Tuesday, August 4th. TD Cowen upped their price target on shares of Adaptive Biotechnologies from $28.00 to $32.00 and gave the company a "buy" rating in a research note on Tuesday, October 13th. Finally, The Goldman Sachs Group assumed coverage on shares of Adaptive Biotechnologies in a report on Tuesday, September 29th. They issued a "buy" rating and a $35.00 price target on the stock. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $30.06.

Adaptive Biotechnologies News Summary

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Adaptive reported earnings of $0.02 per share, versus analysts’ expectation of a $0.10-per-share loss. Management also said the company achieved total-company profitability ahead of expectations. Third-quarter 2026 financial results
• Positive Sentiment: Revenue was $83.9 million, exceeding the $71.57 million analyst estimate. Core measurable residual disease (MRD) revenue grew 44%, a strong growth signal for a key business area. Q3 earnings and revenues top estimates
• Neutral Sentiment: COO Julie Rubinstein sold 11,881 shares under a pre-arranged Rule 10b5-1 trading plan and retained 377,802 shares. The planned nature of the sale may make it less meaningful as a signal about near-term business prospects. Insider share sale
• Negative Sentiment: Revenue was still down 10.7% from the year-ago quarter, tempering the strong results versus analyst estimates. The company also reported a negative net margin. Quarterly earnings report

Adaptive Biotechnologies Trading Up 3.5%

The company has a debt-to-equity ratio of 2.22, a current ratio of 4.79 and a quick ratio of 4.68. The business's 50-day moving average is $26.37 and its 200 day moving average is $19.76. The firm has a market capitalization of $4.26 billion, a P/E ratio of -65.15 and a beta of 2.18.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported $0.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.10) by $0.12. Adaptive Biotechnologies had a negative net margin of 20.73% and a negative return on equity of 36.81%. The firm had revenue of $83.90 million during the quarter, compared to the consensus estimate of $71.57 million. During the same quarter in the previous year, the firm posted $0.06 EPS. The business's revenue for the quarter was down 10.7% compared to the same quarter last year. As a group, analysts anticipate that Adaptive Biotechnologies Corporation will post -0.40 EPS for the current fiscal year.

Institutional Investors Weigh In On Adaptive Biotechnologies

A number of hedge funds and other institutional investors have recently made changes to their positions in ADPT. University of Texas Texas AM Investment Management Co. acquired a new stake in Adaptive Biotechnologies during the third quarter worth approximately $277,000. Ethic Inc. acquired a new position in Adaptive Biotechnologies in the 3rd quarter valued at $244,000. Pictet Asset Management Holding SA raised its holdings in Adaptive Biotechnologies by 12.5% in the 3rd quarter. Pictet Asset Management Holding SA now owns 17,924 shares of the company's stock valued at $518,000 after acquiring an additional 1,985 shares in the last quarter. Parr Mcknight Wealth Management Group LLC acquired a new position in Adaptive Biotechnologies in the 3rd quarter valued at $217,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Adaptive Biotechnologies during the 3rd quarter valued at $236,000. 99.17% of the stock is currently owned by institutional investors and hedge funds.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation NASDAQ: ADPT is a biotechnology company focused on using the genetics of the adaptive immune system to develop diagnostic and research tools. Based in Seattle, Washington, the company analyzes immune-cell receptors to help identify and measure disease, support drug development and improve understanding of immune responses.

Adaptive's products include clonoSEQ, a clinical assay used to detect and monitor measurable residual disease in certain blood cancers, including multiple myeloma, acute lymphoblastic leukemia and chronic lymphocytic leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.